Anticoagulation Management for Pregnant Patients with High-Risk Antiphospholipid Syndrome

Anticoagulation Regimen

The American College of Rheumatology recommends the combination of therapeutic-dose low-molecular-weight heparin (LMWH) and low-dose aspirin throughout pregnancy and postpartum for pregnant women with thrombotic antiphospholipid syndrome (APS) 1
LMWH is preferred over unfractionated heparin (UFH) due to its better safety profile and more predictable pharmacokinetics, as supported by the American Society of Hematology 2
Vitamin K antagonists (warfarin) are contraindicated during the first trimester due to teratogenicity risk, as stated by the American College of Cardiology 4

Routine monitoring of anti-FXa levels to guide LMWH dosing is not strongly recommended, but may be considered in special circumstances, according to the American Society of Hematology 2
Close monitoring for signs of bleeding or thrombosis is essential throughout pregnancy, as emphasized by the American College of Rheumatology 1

Scheduled delivery with prior discontinuation of anticoagulation is recommended for pregnant women receiving therapeutic-dose LMWH, as suggested by the American Society of Hematology 2
Anticoagulation should be resumed postpartum and continued for at least 6-12 weeks, with a minimum total duration of 3 months, as recommended by the American College of Chest Physicians and the American Society of Hematology 2, 5

The addition of hydroxychloroquine (HCQ) to prophylactic-dose heparin or LMWH and low-dose aspirin therapy may be beneficial for patients with primary APS, as suggested by the American College of Rheumatology 1
Triple-positive aPL, strongly positive lupus anticoagulant, advanced maternal age, or IVF pregnancy may warrant more aggressive anticoagulation approaches, according to the American College of Rheumatology 1